ADA 2026 delivered exactly what we expected and then some. New Phase III results. Fresh safety questions. Exciting next-generation therapies. And one growing realization:

The future of obesity medicine is going to be far more complicated than asking which drug produces the most weight loss.

Dave welcomed Jen (@JcanNuSH) back to On The Pen to separate the …